ES014, a dual acting molecule that binds CD39 and Target 2 (undisclosed). It inhibits ATPase activity and target immunosuppressive pathways to promote anti-tumor responses and efficacy. Now, ES104 is currently being evaluated in IND-enabling studies.
MOA:
